Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Objective Response
Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions. Objective tumor response was defined as a PR or CR.
From day of first treatment through Week 25 or at time of discontinuation from study treatment.
United States: Food and Drug Administration
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|
|Montefiore Medical Center||Bronx, New York 10467-2490|
|University of North Carolina at Chapel Hill||Chapel Hill, North Carolina 27599|
|University Of Texas Md Anderson Cancer Ctr||Houston, Texas 77030|
|Dana-Farber Cancer Inst||Boston, Massachusetts 02115|
|Ucsf-Comprehensive Cancer Center||San Francisco, California 94115|
|Mayo Clinic Florida||Jacksonville, Florida 32224|